Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy

Pediatr Infect Dis J. 2010 Aug;29(8):774-7. doi: 10.1097/INF.0b013e3181db741b.

Abstract

Highly active antiretroviral therapy might lead to the development of dyslipidemia and lipodystrophy (LD) syndrome. We carried out a multicenter prospective study of 22 human immunodeficiency virus (HIV)-1-infected children treated during 48 months with lopinavir/ritonavir-based highly active antiretroviral therapy to evaluate the trend of serum lipids and adipokines. Increase in plasma leptin levels and leptin/adiponectin ratio was associated with LD. These adipokines may be surrogate markers of LD.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active / methods
  • Biomarkers
  • Child
  • Child, Preschool
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • HIV-1
  • HIV-Associated Lipodystrophy Syndrome / chemically induced*
  • Humans
  • Infant
  • Leptin / blood*
  • Lopinavir
  • Prospective Studies
  • Pyrimidinones / adverse effects*
  • Pyrimidinones / therapeutic use
  • Ritonavir / adverse effects*
  • Ritonavir / therapeutic use

Substances

  • Anti-HIV Agents
  • Biomarkers
  • Leptin
  • Pyrimidinones
  • Lopinavir
  • Ritonavir